Hidden Bibliographic Details
| Other authors / contributors: | Mita, Monica, editor.
Mita, Alain, editor.
Rowinsky, Eric K., 1956- editor.
|
|---|
| ISBN: | 9782817804927
2817804929
2817805577
9782817805573
9782817804910
2817804910
|
|---|
| Digital file characteristics: | text file
PDF
|
|---|
| Notes: | Includes bibliographical references.
English.
|
|---|
| Summary: | This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.
|
|---|
| Other form: | Printed edition: 9782817804910
|
|---|
| Standard no.: | 10.1007/978-2-8178-0492-7
|
|---|
